Telomir Pharmaceuticals, Inc. Common Stock
NASDAQ:TELOBiotechnology
-$0.04 today
- Market cap
- $50.84M
- Beta
- -0.24
- P/E (TTM)
- -3.8
- EPS (TTM)
- -$0.27
Volume 0.17M
Average 0.13M
TELO Total Current Liabilities
All obligations due within one year.
Telomir Pharmaceuticals, Inc. Common StockNASDAQ: TELO
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities rises 26.8% from a year ago
Total current liabilities stood at $827.31K at the end of Q1 FY2026, up 26.8% from a year earlier and down 42.1% from the prior quarter. Over 3 fiscal years it compounded at +13.1% a year.
Context
- Total current liabilities amounted to 14.3% of total assets at the end of Q1 FY2026, down 118.5 pp from a year earlier.
- Total current liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps rising in the next quarterly balance sheet after a +26.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 1.43M USD
- Year-over-year change
- +109.7%
- 4-year CAGR
- +79.3%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.43M | +109.7% |
| FY2024 | 2024-12-31 | 680.97K | -49.0% |
| FY2023 | 2023-12-31 | 1.34M | +35.5% |
| FY2022 | 2022-12-31 | 986.01K | +613.8% |
| FY2021 | 2021-12-31 | 138.13K | — |
Total Current Liabilities vs competitors
How TELO compares with its peers on the latest reported figures
- TELO's Mar 2026 total current liabilities of $827.31K is the lowest of the 6 companies compared; the peer median is $5.39M.
- Its year-over-year change of +26.8% is the 2nd highest of 6, against a peer median of -32.0%.
- Total current liabilities amounts to 14.3% of total assets for TELO, versus a peer median of 9.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $117.3M | +29.8% | +11.8% | 89.3% | |
| Mar 2026 | $13.57M | -6.5% | -12.1% | 4.2% | |
| Mar 2026 | $5.39M | -32.0% | -8.3% | 20.9% | |
| Mar 2026 | $3.35M | -44.3% | -54.9% | 5.3% | |
| Mar 2026 | $1.82M | -67.8% | -6.6% | 9.2% | |
| Mar 2026 | $827.31K | +26.8% | +13.1% | 14.3% | |
| Peer median (excluding TELO) | $5.39M | -32.0% | -8.3% | 9.2% | |
Competitors are the stored peer set for TELO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Telomir Pharmaceuticals, Inc. Common Stock
NASDAQ:TELO
Intrinsic Alpha fair value
Locked
Current Price
$0.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.